News

Lebrikizumab, developed by Genentech Research and Early Development, is a humanized monoclonal antibody designed to block the IL-13 cytokine and reduce inflammation in the lung. The study, which

For the second quarter of 2011, the company has posted net income of $56.36m, or $0.17 per diluted share, compared to $33.97m, or $0.21 per diluted share, for

The multicenter, open-label, randomized study was designed to assess the safety and tolerability of hGH-CTP in growth hormone deficient adults. The data demonstrated that a single weekly injection

The results of the trial suggested that MDV3100 inhibits proliferation of breast cancer cells. The results demonstrated that androgens dihydrotestosterone (DHT) or R1881 treatment had a proliferative effect

The company intends to conduct the research work in cooperation with the University of British Columbia and the BC Cancer Agency. The data from preclinical trials showed anti-cancer

LabPartner is a provider of lab equipment, reagents, consumables and services for research and development. LabPartner delivers products and integrated services, with a focus on chemical distribution to

Roche‘s Boulder plant, engaged in the production of therapeutic peptide compounds, is equipped with large scale synthetic manufacturing technologies. The agreement allows ICIG to take over the technical

As per the terms of the agreement, GSK is responsible to pay up to EUR5.5m to MolMed in revenues for a term of two-year. Developed by the San

For the second quarter of 2011, the company has posted net loss of $51.51m, or $0.45 loss per diluted share, compared to $8.32m, or $0.08 loss per diluted